Reumatología Clínica Reumatología Clínica
Reumatol Clin. 2011;07:262-6 - Vol. 07 Num.04

Rheumatoid arthritis: How to use drugs during pregnancy and lactation?

Erardo Meriño-Ibarraa,, Concepción Delgado Beltrána

a Hospital Clínico Universitario Lozano Blesa, Zaragoza, España

Keywords

Artritis reumatoide. Inmunosupresores. Embarazo. Lactancia.

Abstract

La artritis reumatoide es una enfermedad que tiene una alta prevalencia en mujeres en edad fértil. Se realiza una revisión de las características de la barrera placentaria, el paso de medicamentos a través de ella y del uso de fármacos durante el embarazo: los que son potencialmente seguros, los fármacos que sólo pueden ser usados si la vida materna se ve comprometida, los fármacos que están contraindicados y aquéllos con información insuficiente sobre seguridad y que por tanto deben ser evitados, en este último grupo se ubican los fármacos biológicos. También se realiza una revisión acerca del uso de fármacos durante la lactancia, periodo en el cual es frecuente un rebrote de la artritis reumatoide.

This article is only available in PDF

Bibliography

1.Bernas BL. Rheumatoid arthritis and pregnancy. En UpToDate, Rose BD, editor. UpToDate. Waltham, MA; 2010.
2.Barrett J, Brennan P, Fiddler M, Silman AJ. Does Rheumatoid arthritis remit during pregnancy and relapse postpartum?. Arthritis Rheum. 1999; 45:1219-27.
3.de Man YA, Dolhain RJ, van de Geijn FE, Willemsen SP, Hazes JM. Disease activity of rheumatoid arthritis during pregnancy: Results from a Nationwide Prospective Study. Arthritis Rheum. 2008; 59:1241-8.
Medline
4.∅stensen M, Förger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol. 2009; 5:382-90.
Medline
5.Gayed M, Gordon C. Pregnancy and rheumatic diseases. Rheumatology. 2007; 46:1634-40.
Medline
6.∅stensen M, Forger F, Nelson JL, Schuhmacher A, Hebisch G, Villiger PM. Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann Rheum Dis. 2005; 64:839-44.
Medline
7.Nelson JL, Kathleen A, Hughes BS, Anajane GS, Smith MA, Nisperos BB, et-al. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med. 1993; 329:466-71.
Medline
8.Purizaca-Benites M. La placenta y la barrera placentaria. Rev Per Ginecol Obstet. 2008; 54:270-8.
9.Guyton AC, Hall JE. Embarazo y lactancia. En: Guyton A.C., Hall J.E., editors. Tratado de fisiología médica. 11a ed. Barcelona: Elsevier España; 2006. 1027-41.
10.Ostrea EM, Mantaring JB, Silvestre MA. Drugs that affect the fetus and newborn infant via the placenta or breast milk. Pediatr Clin North Am. 2004; 51:539-79.
Medline
11.Hunt JS. Immunology of the maternal-fetal interface. En UpToDate, Rose BD, editor. UpToDate. Waltham, MA; 2010.
12.Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJ. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology. 1996; 54:84-92.
Medline
13.Ericson A, Källén BAJ. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reproductive Toxicology. 2001; 15:371-5.
Medline
14.Calvo Allen J. Tratamiento de situaciones clínicas difíciles en pacientes con artritis reumatoide: embarazo. Reumatol Clin. 2009; 5:48-52.
15.Cetinkal A, Colak A, Topuz K, Demircan MN, Simsek H, Berber U, et-al. The effects of meloxicam on neural tube development in the early stage of chick embryos. Turk Neurosurg. 2010; 20:111-6.
Medline
16.Bernas BL. Use of immunosuppressive drugs in pregnancy and lactation. En UpToDate, Rose BD, editor. UpToDate. Waltham, MA; 2010.
17.Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et-al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000; 62:385-92.
Medline
18.Hernandez-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000; 343:1608-14.
Medline
19.∅stensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et-al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006; 8:209-28.
Medline
20.Moráin CO, Smethurst P, Doré CJ, Levi AJ. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut. 1984; 25:1078-84.
Medline
21.Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DLT, Sebbough D, Wechsler B, et-al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. A study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003; 48:3207-11.
Medline
22.Nørgård B, Pedersen L, Christensen LA, Sørensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol. 2007; 102:1406-13.
Medline
23.Armenti VT, Ahlswede KM, Ahlswede BA, Jarrell BE, Moritz MJ, Burke JF. National transplantation Pregnancy Registry--outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation. 1994; 57:502-6.
Medline
24.Kainz A, Harabacz I, Cowlrick IS, Gadgil SD, Hagiwara D. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation. 2000; 70:1718-21.
Medline
25.Paladini D, Vassallo M, D’Armiento MR, Cianciaruso B, Martinelli P. Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the first trimester of pregnancy. Birth Defects Res A Clin Mol Teratol. 2004; 70:99-100.
Medline
26.Almarzouqi M, Scarsbrook D, Klinkhoff A. Gold therapy in women planning pregnancy: Outcomes in One Center. J Rheumatol. 2007; 34:1827-31.
Medline
27.Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, et-al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010; 62:1494-503.
Medline
28.Pérez-Aytes A, Ledo A, Boso V, Sáenz P, Roma E, Poveda JL, et-al. In utero exposure to mycophenolate mofetil: A characteristic phenotype?. Am J Med Genet A. 2008; 146A:1-7.
Medline
29.Pache I, Rogler G, Felley Ch. TNF-α blockers in inflammatory bowel disease: Practical consensus recommendations and user's guide. Swiss Med Wkly. 2009; 139:278-87.
Medline
30.Roux C, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy. Rheumatology. 2007; 46:695-8.
Medline
31.Ali YM, Kuriya B, Orozco C, Cush JJ, Keystone EC. Can tumor necrosis factor inhibitors be safely used in pregnancy?. J Rheumatol. 2010; 37:9-17.
Medline
32.Umeda N, Ito S, Hayashi T, Goto D, Matsumoto I, Sumida T. A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment. Inter Med. 2010; 49:187-9.
33.Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004; 99:2385-92.
Medline
34.∅stensen M, Lockshin M, Doria A, Valesini G, Meroni P, Gordon C, et-al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology. 2008; 47:iii28-31.
Medline
35.Oussalah A, Bigard MA, Peyrin-Biroulet L. Certolizumab use in pregnancy. Gut. 2009; 58:608.
Medline
36.Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum. 2009; 61:587-92.
Medline
37.Ilett KF, Kristensen JH. Drug distribution in human milk. Aust Prescr. 1997; 20:35-40.